Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: A phase II trial

Journal of Clinical Oncology

Volumn 16, Issue 8, 1998, Pages 2722-2727

  Bajorin, Dean F ^a   McCaffrey, John A ^a   Hilton, Susan ^a   Mazumdar, Madhu ^a   Kelly, W Kevin ^a   Scher, Howard I ^a   Spicer, Jacqueline ^a   Herr, Harry ^a   Higgins, Geralyn ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; IFOSFAMIDE; MANNITOL; MESNA; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ALLERGY; ALOPECIA; ANEMIA; ARTICLE; BLADDER CARCINOMA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MALE; NEUROPATHY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; URINARY TRACT CARCINOMA;

EID: 0031903265     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.8.2722     Document Type: Article

References (30)

1. Scher H: Should single agents be standard therapy for urothelial tract tumors? J Clin Oncol 10:694-697, 1989
2. Sternberg CN, Yagoda A, Scher HI, et al: Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell carcinoma of the urothelium. Cancer 64:2448-2485, 1989
3. Harker WG, Meyers FJ, Freiha FS, et al: Cisplatin, methotrexate and vinblastine (CMV): An effective chemotherapy regimen for metastatic transitional cell carcinoma of the urothelial tract. A Northern California Oncology Group study. J Clin Oncol 3:1463-1470, 1985
4. Loehrer PJ, Einhorn LH, Elson PJ, et al: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: A Cooperative Group study. J Clin Oncol 10:1066-1073, 1992
5. Logothetis CJ, Dexeus FH, Finn L, et al: A prospective randomized trial comparing M-VAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8:1050-1055, 1990
6. Saxman SB, Propert KJ, Einhorn LH, et al: Long-term follow-up of phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 15:2564-2569, 1997
7. Logothetis CJ, Finn LD, Smith T, et al: Escalated M-VAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial. J Clin Oncol 13:2272-2277, 1995
8. Seidman AD, Scher HI, Gabrilove JL, et al: Dose-intensification of methotrexate, vinblastine, doxorubicin, and cisplatin with recombinant granulocyte-colony stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol 11:408-414, 1993
9. Gabrilove JL, Jakubowski A, Scher HI, et al: Effect of granulocyte colony-stimulating factor in neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium. N Engl J Med 318:1414-1422, 1988
10. Moore MJ, Tannock IF, Iscoe N, et al: A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) + GM-CSF in patients with advanced transitional cell carcinoma. Am Proc Soc Clin Oncol 11:199, 1992 (abstr 611)
11. Loehrer PJ, Nichols CR, Elson P, et al: Escalated dosages of methotrexate, vinblastine, doxorubicin and cisplatin plus rh-G-CSF in advanced urothelial carcinoma: An ECOG trial. J Clin Oncol 12:483-488, 1994
12. Sternberg C, de Mulder P, van Oosterom AT, et al: Intensified M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with advanced urothelial tract tumors. Proc Am Soc Clin Oncol 11:210, 1992 (abstr 653)
13. Roth BJ, Dreicer R, Einhorn LH: Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12:2264-2270, 1994
14. Gad-el-Mawla N, Hamza MR, Zikri ZK, et al: Chemotherapy in invasive carcinoma of the bladder. A review of phase II trials in Egypt. Acta Oncol 28:73, 1989
15. Khaled HM, Gad-el-Mawla N, el-Said A, et al: Combination chemotherapy for advanced bilharzial bladder cancer. Ann Oncol 7:751-754, 1996
16. Otaguro K, Ueda K, Niijma T, et al: Clinical evaluation of Z4942 (ifosfamide) for malignant urological tumors. Acta Urol Jpn 27:459, 1981
17. Witte R, Loehrer P, Dreicer R, Williams S, Elson P. Ifosfamide (IFX) in advanced urothelial carcinoma: An ECOG trial. Proc Am Soc Clin Oncol 12:230, 1993 (abstr)
18. Schilder LE, Albain KS, Hantel A, et al: Phase I trial of Taxol, ifosfamide, cisplatin (TIC) in patients with solid tumors. Proc Am Soc Clin Oncol 14:101, 1995 (abstr 103)
19. Kaplan EL, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457-481, 1958
20. Schultz P, et al: Neo-adjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. J Clin Oncol 12:1394-1401, 1994
21. Herr HW, Scher HI: Neo-adjuvant chemotherapy and partial cystectomy for invasive bladder cancer. J Clin Oncol 12:975-980, 1994
22. Splinter TA, Scher HI, Denis L, et al: The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer-Genitourinary Group. J Urol 147:606-608, 1992
23. Roth BJ, Finch DE, Birhle R, et al: A phase II trial of ifosfamide and paclitaxel in advanced transitional cell carcinoma of the urothelium. Proc Am Soc Clin Oncol 16:324, 1997 (abstr 1156)
24. Roth BJ: The role of ifosfamide in the treatment of testicular and urothelial malignancies. Semin Oncol 23:19-27, 1996 (suppl 7)
25. Motzer RJ, Cooper K, Geller NL, et al: The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors. Cancer 66:2476-2481, 1990
26. McCaffrey JA, Hilton S, Mazumdar M, et al: Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 15:1853-1857, 1997
27. Khorsand M, Lange J, Feun L, et al: Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder. Invest New Drugs 15:157-163, 1997
28. Stadler WM, Kuzel T, Roth B, et al: Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15:3394-3398, 1997
29. Moore MJ, Tannock IF, Ernst DS, et al: Gemcitabine: A promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 15:3441-3445, 1997
30. Norton L, Simon R: The Norton-Simon hypothesis revisited. Cancer Treat Rep 70:163-169, 1986